Effects of morin on the pharmacokinetics of etoposide in rats

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 3, 2007, Pages 151-156

  Li, Xiuguo ^a,b   Yun, Jae Kyung ^a   Choi, Jun Shik ^a  

^a Chosun University   (South Korea)

^b YANBIAN UNIVERSITY   (China)

Author keywords

Bioavailability; Etoposide; Morin; P gp; Pharmacokinetics; Rats

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; ETOPOSIDE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; ISOENZYME; MORIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME INHIBITION; INTESTINE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; STATISTICAL SIGNIFICANCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ETOPOSIDE; FLAVONOIDS; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY; LIVER; MALE; P-GLYCOPROTEIN; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 34248327577     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.539     Document Type: Article

References (34)

1. Wozniak AJ, Ross WE. DNA damage as a basis for 4′- demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity. Cancer Res 1983; 43: 120-124.
2. Clark PI, Slevin ML. The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 1987; 12: 223-252.
3. van Maanen JM, de Vries J, Pappie D, et al. Cytochrome P-450-mediated O-demethylation: a route in the metabolic activation of etoposide (VP-16-213). Cancer Res 1987; 47: 4658-4662.
4. Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ, Korzekwa KR. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 1994; 45: 352-358.
5. Kawashiro T, Yamashita K, Zhao XJ, et al. A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther 1998; 286: 1294-1300.
6. Leu BL, Huang JD. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 1995; 35: 432-436.
7. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporin in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635-1642.
8. Carcel-Trullols J, Torres-Molina F, Araico A, Saadeddin A, Peris JE. Effect of cyclosporin A on the tissue distribution and pharmacokinetics of etoposide. Cancer Chemother Pharmacol 2004; 54: 153-160.
9. Keller RP, Altermatt HJ, Donatsch P, Zihlmann H, Laissue JA, Hiestand PC. Pharmacologic interactions between the resistance-modifying cyclosporin SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int J Cancer 1992; 51: 433-438.
10. Kok LD, Wong YP, Wu TW, Chan HC, Kwok U, Fung KP. Morin hydrate: a potential antioxidant in minimizing the free-radicals-mediated damage to cardiovascular cells by anti-tumor drugs. Life Sci 2000; 67: 91-99.
11. Francis AR, Shetty TK, Bhattacharya RK. Modulating effect of plant flavonoids on the mutagenicity of N-methyl-N′-nitro-N-nitrosoguanidine. Carcinogenesis 1989; 10: 1953-1955.
12. Fang SH, Hou YC, Chang WC, Hsiu SL, Chao PD, Chiang BL. Morin sulfates/ glucuronides exert anti-inflammatory activity on activated macrophages and decreased the incidence of septic shock. Life Sci 2003; 74: 743-756.
13. Kitagawa S, Nabekura T, Takahashi T, et al. Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol Pharm Bull 2005; 28: 2274-2278.
14. Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 2003; 304: 1258-1267.
15. Choi JS, Han HK. Pharmacokinetic interaction between diltiazem and morin, a flavonoid, in rats. Pharmacol Res 2005; 52: 386-391.
16. Hertog MG, Hollman PC, Katan MB, Kromhout D. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr Cancer 1993; 20: 21-29.
17. Hertog MG, Kromhout D, Aravanis C, et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med 1995; 155: 381-386.
18. Knekt P, Jarvinen R, Seppanen R, et al. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am J Epidemiol 1997; 146: 223-230.
19. Rimm EB, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Relation between intake of flavonoids and risk for coronary heart disease in male health professionals. Ann Intern Med 1996; 125: 384-389.
20. Choi HJ, Choi JS. Effects of morin pretreatment on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem in rats. Arch Pharm Res 2005; 28: 970-976.
21. Choi JS, Burm JP. Enhanced nimodipine bioavailability after oral administration of nimodipine with morin, a flavonoid, in rabbits. Arch Pharm Res 2006; 29: 333-338.
22. Choi BC, Choi JS, Han HK. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats. Int J Pharm 2006; 323: 81-85.
23. Liliemark E, Pettersson B, Peterson C, Liliemark J. High-performance liquid chromatography with fluorometric detection for monitoring of etoposide and its cis-isomer in plasma and leukaemic cells. J Chromatogr B Biomed Appl 1995; 669: 311-317.
24. Manouilov KK, McGuire TR, Gordon BG, Gwilt PR. Assay for etoposide in human serum using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 1998; 707: 342-346.
25. Chiou WL. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978; 6: 539-546.
26. Gibaldi M, Perrier D. Pharmacokinetics (2nd edn). Marcel Dekker: New York, 1982.
27. Rocci ML, Jusko WJ. LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed 1983; 16: 203-216.
28. Kim SK Choi YM, Lee MG. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 1993; 21: 1-17.
29. Chiou WL. New calculation method of mean total body clearance of drugs and its application to dosage regimens. J Pharm Sci 1980; 69: 90-91.
30. Eatman FB, Colburn WA, Boxenbaum HG, et al. Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 1977; 5: 481-494.
31. Chiou WL. New calculation method for mean apparent drug volume of distribution and application to rational dosage regimen. J Pharm Sci 1979; 68: 1067-1069.
32. Hou YC, Chao PD, Ho HJ, Wen CC, Hsiu SL. Profound difference in pharmacokinetics between morin and its isomer quercetin in rats. J Pharm Pharmacol 2003; 55: 199-203.
33. Hsiu SL, Tsao CW, Tsai YC, Ho HJ, Chao PD. Determinations of morin, quercetin and their conjugate metabolites in serum. Biol Pharm Bull 2001; 24: 967-969.
34. Lo YL, Huang JD. Comparison of effects of natural or artificial rodent diet on etoposide absorption in rats. In Vivo 1999; 13: 51-55.